Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide

British Journal of Cancer

Volumn 73, Issue 10, 1996, Pages 1201-1209

  Vassetzky, Y S ^a,b   Alghisi, G C ^a   Roberts, E ^a   Gasser, S M ^a  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^b INSTITUT JACQUES MONOD   (France)

Author keywords

Drug resistance; Etoposide; Teniposide; Topoisomerase II; Yeast

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME INACTIVATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

EID: 0029896892     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.231     Document Type: Article

References (45)

1. ALGHISI G-C, ROBERTS E, CARDENAS ME AND GASSER SM. (1994). The regulation of DNA lopoisomerase II by casein kinase II. Cell Mol. Biol. Res., 40, 563-572.
2. ALTON PA AND HARRIS AL. ((1993). The role of DNA topoisomerase II in drug resistance. Br. J. Haematol., 85, 241-245.
3. BECK WT, DANKS MK, WOLVERTON JS, KIM R AND CHEN M. (1993). Drug resistance associated with altered DNA topoisomerase II. Adv. Enz. Regulation, 33, 113-127.
4. BUGG BY, DANKS MK, BECK WT AND SUTTLE DP. (1991). Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl Acad. Sci. USA, 88, 7654-7658.
5. CAMPAIN JA, GOTTESMAN MM AND PASTAN I. (1994). A novel mutant topoisomerase IIα present in VP-16-resistant melanoma cell lines has a deletion of alanine 429. Biochemistry, 33, 11327-11332.
6. CARDENAS ME AND GASSER SM. (1993). Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. J. Cell. Sci., 104, 219-225.
7. CARDENAS ME, DANG Q, GLOVER CVC AND GASSER SM. (1992). Casein kinase II phosphorylates with eukaryotic-specific C-terminal domain of topoisomerase II in vivo. EMBO J., 11, 1785-1796.
8. CARON PR, WATT P AND WANG JC. (1994). The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II. Mol. Cell Biol., 14, 3197-3207.
9. CHAN VT, NG SW, EDER JP AND SCHNIPPER LE. (1993). Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem., 268, 2160-2165.
10. CORBETT AH AND OSHEROFF T. (1993). When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 6, 585-597.
11. CRENSHAW DG AND HSIEH T. (1993a). Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. I. in vitro studies J. Biol. Chem., 268, 21328-21334.
12. CRENSHAW DG AND HSIEH T. (1993b). Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. II. In vivo studies. J. Biol. Chem., 268, 21335-21343.
13. DANG O, ALGHISI G-C AND GASSER SM. (1994). Phosphorylation of the C-terminal domain of yeast topoisomerase II by casein kinase II affects DNA-protein interaction. J. Mol. Biol., 243, 10-24.
14. DANKS MK, WARMOTH MR, FRICHE E, GRANZEN B, BUGG BY, HARKER WG, ZWELLING LA, FUTSCHER BW, SUTTLE DP AND BECK WT. (1993). Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumour cells. Cancer Res., 53, 1373-1379.
15. DEVORE RF, CORBETT AH AND OSHEROFF N. (1992). Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects on enzyme-mediated DNA cleavage, religation and sensitivity to the antineoplastic drugs etoposide and m-AMSA. Cancer Res., 52, 2156-2161.
16. DINARDO S, VOELKEL K AND STERNGLANZ R. (1984). DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecule at the termination of DNA replication. Proc. Natl Acad. Sci. USA, 82, 2616-2620.
17. EDER JJ, CHAN VT, NIEMIERKO E, TEICHER BA AND SCHNIPPER LE. (1993). Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J. Biol. Chem., 268, 13844-13849.
18. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
19. FELDHOFF PW, MIRSKI SE, COLE SP AND SULLIVAN DM. (1994). Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res., 54, 756-762,
20. GANAPATHI R, ZWELLING L, CONSTANTINOU A, FORD J AND GRABOWSKI D. (1993). Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Biomed. Biophys. Res. Commun., 192, 1274-1280.
21. GRANZEN B, GRAVES DE, BAGULEY BC, DANKS MK AND BECK WT. (1992). Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein. Oncol. Res., 4, 489-496.
22. GUDKOV AV, ZELNICK CR, KAZAROV AR, THIMMAPAYA R, SUTTLE DP, BECK WT AND RONINSON IB. (1993). Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl Acad. Sci. USA, 90, 3231-3235.
23. HINDS M, DEISSEROTH K, MAYES J, ALTSCHULER E, JANSEN R, LEDLEY FD AND ZWELLING LA. (1991). Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res., 51, 4729-4731.
24. JANNATIPOUR M, LIU YX AND NITISS JL. (1993). The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J. Biol. Chem., 268, 18586-18592.
25. KLEIN F, LAROCHE T, CARDENAS ME, HOFMANN JF, SCHWEIZER D AND GASSER SM. (1992). Localization of RAP1 and topoisomerase II in nuclei and meiotic chromosomes of yeast. J. Cell Biol., 117, 935-948.
26. LEE MS, WANG JC AND BERAN M. (1992). Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol., 223, 837-843.
27. LIU LF. (1989). DNA topoisomerase poisons as antitumour drugs. Annu. Rev. Biochem., 58, 351-375.
28. LIU LF AND D'ARPA P. (1992). Topoisomerase-targeting antitumour drugs: mechanisms of cytotoxicity and resistance. Impt. Adv. in Oncol., 79-89.
29. LIU YX, HSIUNG Y, JANNATIPOUR M, YEH Y AND NITISS JL. (1994). Yeast topoisomerase II mutants resistant to antitopoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res., 54, 2943-2951.
30. LONG BH, WANG L, LORICO A, WANG RC, BRATTAIN MG AND CASAZZA AM. (1991). Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res., 51, 5275-5283.
31. MCPHERSON JP, BROWN GA AND GOLDENBERG GJ. (1993). Characterization of a DNA topoisomerase IIα gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIα and the retinoic acid receptor alpha locus. Cancer Res., 53, 5885-5889.
32. NITISS J AND WANG JC. (1988). DNA topoisomerase-targeting antitumour drugs can be studied in yeast. Proc. Natl Acad. Sci. USA, 85, 7501-7505.
33. NITISS JL, LIU YX, HARBURY P, JANNATIPOUR M, WASSERMAN RA AND WANG JC. (1992). Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 52, 4467-4472.
34. PALLADINO F, LAROCHE T, GILSON E, AXELROD A, PILLUS L AND GASSER SM. (1993). SIR3 and SIR4 proteins are required for the positioning and integrity of yeast telomeres. Cell, 75, 543-555.
35. POMMIER Y. (1993). DNA topoisomerase I and II in cancer therapy: update and perspectives. Cancer Chemother. Pharmacol., 3, 103-108.
36. ROSE MD, WINSTON F AND HEITER P. (1990). Methods in Yeast Genetics. A Laboratory Course Manual, pp. 198, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.
37. SHIOZAKI K AND YANAGIDA M. (1991). A functional 125-kDa core polypeptide of fission yeast DNA topoisomerase II. Mol. Cell Biol., 11, 6093-6102.
38. TAKANO H, KOHNO K, ONO M, UCHIDA Y AND KUWANO M. (1991). Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res., 51, 3951-3957.
39. VASSETZKY YS, ALGHISI G-C AND GASSER SM. (1995). DNA topoisomerase II mutations and resistance to anti-tumour drugs. BioEssays, 17, 767-774.
40. WANG JC. (1985). DNA topoisomerase. Annu. Rev. Biochem., 54, 665-697.
41. WASSERMAN RA AND WANG JC. (1994a). Analysis of yeast DNA topoisomerase II mutants resistant to the antitumour drug amsacrine. Cancer Res., 54, 1795-1800.
42. WASSERMAN RA AND WANG JC. (1994b). Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. J. Biol. Chem., 269, 20943-20951.
43. WASSERMAN RA, AUSTIN CA, FISHER LM AND WANG JC. (1993). Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast. Cancer Res., 53, 3591-3596.
44. WATT PM AND HICKSON ID. (1994). Structure and function of type II DNA topoisomerases. Biochem. J., 303, 681-695.
45. WORLAND ST AND WANG JC. (1989). Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast. Saccharomyces cerevisiae. J. Biol. Chem., 264, 4412-4416.